Kyowa Kirin CoKYKOF 82 ROE % is 15.43% as of Dec. 2025, which is 113% above its 10-year median of 7.24. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 936 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 59.62% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Kyowa Kirin Co's annualized net income for the quarter that ended in Dec. 2025 was $884 Mil. Kyowa Kirin Co's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $5,726 Mil. Therefore, Kyowa Kirin Co's annualized ROE % for the quarter that ended in Dec. 2025 was 15.43%.
The historical rank and industry rank for Kyowa Kirin Co's ROE % or its related term are showing as below:
KYKOF'
s ROE % Range Over the Past 10 Years
Min: 5.11 Med: 7.24 Max: 10.15
Current: 8.47
During the past 13 years, Kyowa Kirin Co's highest ROE % was 10.15%. The lowest was 5.11%. And the median was 7.24%.
KYKOF's ROE % is ranked better than 59.62% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs KYKOF: 8.47
Kyowa Kirin Co (OTCPK:KYKOF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Kyowa Kirin Co ROE % Related Terms
Kyowa Kirin Co ROE % Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's ROE % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Kyowa Kirin Co (KYKOF) has a ROE % of 15.43% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kyowa Kirin Co and its competitors. This is 113% above median its historical median of 7.24. Over the past decade, Kyowa Kirin Co's ROE % has ranged from 5.11 to 10.15. According to the industry distribution chart, Kyowa Kirin Co ranks #378 out of 936 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is Kyowa Kirin Co's ROE % too high?
Kyowa Kirin Co's current ROE % of 15.43% is 113% above median its 10-year median of 7.24. Over the past 10 years, this metric has ranged from a low of 5.11 to a high of 10.15. The Drug Manufacturers industry median ROE % is 5.87. Kyowa Kirin Co's value of 15.43% is 163.1% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #378 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #378 out of 936 companies for ROE %. This puts Kyowa Kirin Co in the upper half of its industry. The industry median ROE % is 5.87. Kyowa Kirin Co's value of 15.43% is 163.1% above this benchmark. Historically, Kyowa Kirin Co's own ROE % has ranged from 5.11 to 10.15 over the past decade. While the company's 10-year median is 7.24 vs. the industry median of 5.87, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current ROE % of 15.43% is 163.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current ROE % is 15.43%, which is 113% above median its own 10-year median of 7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current ROE % is 15.43%, which is 113% above median its 10-year median of 7.24 and 163.1% above the Drug Manufacturers industry median of 5.87. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current ROE % is 15.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
ROE %: 15.43% (113% above median its 10-year median of 7.24)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 163.1% above the Drug Manufacturers median (#378 of 936)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
